The day at a glance · 5 sections · 3 min read
Mood · Cautious Optimism
+35
Sentiment, −100 to +100
Pfizer Q3 Revenue
$16.6B
Pfizer 2026 Revenue Guidance
$62-64B
Pfizer 2026 EPS Guidance
$2.95-3.05
Key driverMajor pharmaceutical earnings reports drove sector sentiment as Pfizer and Amgen raised full-year guidance while licensing activity accelerated
Daily briefHealthcare· Money365.Market AI ·
Pfizer, Amgen Lift Guidance; AbbVie Lands $1.37B Deal
Big Pharma earnings beat expectations; Nxera licenses inflammatory bowel disease candidate to AbbVie in upfront-plus-milestones pact
Big Pharma Earnings Beat Expectations
BullishPfizer Non-COVID Growth
7%+7%
Pfizer Launched/Acquired Growth
32%+32%
Amgen Q3 Revenue
$10.4B+8%
Amgen Growth Drivers
27%+27%
01PFE▼ -2.18%
Pfizer (PFE) reported third-quarter revenue of $16.6 billion and raised its full-year 2026 revenue guidance to $62 billion to $64 billion, with adjusted earnings per share guidance lifted to $2.95 to $3.05. Non-COVID products grew 7% operationally while launched and acquired products surged 32%, according to the company. The company appointed Cecile Guegan as Chief Financial Officer. Chief Executive Officer Albert Bourla cited growth in the company's launched and acquired medicines as a key driver of the raised outlook.
02AMGN
Amgen (AMGN) reported third-quarter revenue growth of 8% year over year to $10.4 billion, supported by broad-based demand across its portfolio and continued clinical progress in several late-stage programs. The company raised its full-year revenue and adjusted earnings outlook, with six key growth drivers surging 27% while offsetting a TEPEZZA decline. The company highlighted pending MariTide data and continued progress across multiple programs as management discussed portfolio expansion opportunities.
03LLY
Eli Lilly (LLY) featured in multiple analyst reports highlighting strong tirzepatide demand driving revenue growth, though pricing and patent risks remain considerations for the company's outlook. Analysts noted higher volume metrics offset by lower realized prices across key products. The company was cited among top growth drivers in the healthcare sector alongside semiconductor and AI infrastructure companies.
M&A and Licensing Activity Accelerates
BullishAbbVie-Nxera Upfront
$100M
AbbVie-Nxera Milestones
$1.37B
01ABBV
AbbVie (ABBV) entered into a global license agreement with Nxera Pharma for NXE0033744, a novel EP4 receptor agonist for inflammatory bowel disease. Nxera will receive $100 million upfront and be eligible for up to $1.37 billion in development and commercial milestone payments, plus tiered royalties. The investigational oral EP4 receptor agonist was discovered using Nxera's NxWave drug discovery platform and is positioned as a potential first-in-class candidate for inflammatory bowel disease treatment.
02GILD
BioNTech and Gilead Sciences (GILD) announced a clinical trial collaboration to test a novel first-line treatment approach in metastatic triple-negative breast cancer through a global Phase 3 study. The partnership centers on BioNTech's bispecific immunomodulator pumitamig combined with a Gilead antibody-drug conjugate. The new regimen targets patients with an aggressive breast cancer subtype where existing treatment options and outcomes remain limited, with BioNTech positioning this as its first global Phase 3 trial for breast cancer combination therapy.
MedTech Leadership & Board Appointments
Neutral01DXCM▼ -2.11%
Guardant Health announced the appointment of Kevin Sayer to its board of directors. Sayer is former CEO of Dexcom (DXCM) and current Executive Chairman of the Dexcom board, with decades of strategic leadership experience in digital health technology. The precision oncology company highlighted Sayer's experience in scaling digital health platforms as a key addition to board expertise.
Biotech Margin Profiles Draw Investor Attention
NeutralGilead Margin
88%
01GILD
Gilead Sciences (GILD) was cited as trading near 52-week highs with an 88% margin profile, prompting analysis of valuation metrics relative to growth prospects. The biotech company's collaboration with BioNTech on triple-negative breast cancer treatment added to pipeline expansion efforts. Analysts examined whether the current valuation reflects the company's margin strength and late-stage pipeline opportunities.
Looking Ahead
NeutralMRK
01
Nxera Pharma revised its consolidated financial forecast for the year ending December 31, 2026, with updated projections replacing guidance previously announced in February 2026.
02
Moderna faces potential manufacturing scale challenges for its cancer vaccine despite promising clinical results, according to analyst commentary. Federal Reserve rate policy continues to influence healthcare sector valuations, with analysts examining historical performance patterns from 2022 when rates rose aggressively and certain healthcare stocks gained more than 80%.
Important Disclaimer — Not Investment Advice
Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.
Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest
Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.
- You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
- Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
- Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
- Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
- We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
- Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
- Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.
Full terms: Disclaimer · Terms of Service · Privacy Policy